A $1.65 Billion Cash Takeover and Non-Opioid Expansion
The international pharmaceutical landscape recorded a decisive consolidation milestone as Pennsylvania-headquartered Viatris announced an agreement to purchase Pacira BioSciences for $1.65 billion in cash. Offering $36.50 per share—a 44.8% premium over closing equity values—the transaction sparked widespread institutional investor interest during early Thursday trading sessions.
At the operational center of the transaction are Pacira's two proprietary non-opioid pharmaceutical assets: Exparel, a long-acting post-surgical infiltration therapy that generated $575.1 million in net sales during 2025, and Zilretta, an extended-release intra-articular injection treating osteoarthritis knee pain that produced $116.6 million. These commercialized therapies inject roughly $700 million in established baseline sales into Viatris, providing an expansive foundation for international commercial scale.
The addition of these therapies is synergistic with our fast-acting meloxicam market opportunity and positions us as an unquestioned leader in non-opioid pain management.
Management anticipates closing the transaction prior to the conclusion of 2026, confirming that the purchase will be immediately accretive to consolidated earnings metrics while preserving a conservative gross leverage profile.















